Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Earnings for Idorsia Ltd (IDIA.SW)
Earnings in 2023 (TTM): $-329,316,474
According to Idorsia Ltd's latest financial reports the company's current earnings (TTM) are $-329,316,474. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Idorsia Ltd
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-329,316,474 | $-333,421,557 |
| 2022 | $-917,811,605 | $-926,548,894 |
| 2021 | $-710,448,983 | $-710,213,959 |
| 2020 | $-502,815,524 | $-498,159,814 |
| 2019 | $-543,013,548 | $-553,591,857 |
| 2018 | $-434,039,724 | $-432,432,609 |
| 2017 | $-16,897,092 | $-15,969,308 |
| 2016 | $-376,814,785 | $-375,078,967 |